Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 18:99:100721.
doi: 10.1016/j.curtheres.2023.100721. eCollection 2023.

Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review

Geetika M Ahlawat  1 , Prabhat K Singh  2   3
Affiliations
Review

Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review

Geetika M Ahlawat et al. Curr Ther Res Clin Exp. .

Abstract

Background: Irritable bowel syndrome (IBS) is a prevalent lifestyle-associated ailment linked to the gut microbiota that significantly influences patients' quality of life. A notable correlation exists between Blastocystis infections and susceptibility to IBS, with infected individuals exhibiting an increased likelihood of developing the condition. Despite promising results from using probiotics to modulate the gut microbiota and manage IBS, the precise mechanisms and potential risks remain unclear.

Objective: This review aims to explore the therapeutic potential of probiotics, particularly Saccharomyces boulardii, in the management of IBS, highlighting the role of the gut microbiota and the gut-brain axis in IBS pathophysiology.

Methods: A comprehensive literature survey was conducted to examine the association between gut microbiota and IBS, the role of probiotics in managing IBS, the mechanisms of their action, and the potential risks associated with their long-term use. Additionally, this study addresses the influence of Blastocystis infections on IBS susceptibility and evaluates various ongoing clinical trials investigating probiotic use for IBS.

Results: S boulardii, a yeast species with probiotic properties, has demonstrated effectiveness in both the treatment and prophylaxis of IBS. Its administration is associated with a decrease in the proinflammatory cytokine interleukin 8 and an increase in the anti-inflammatory cytokine interleukin 10. Probiotics appear to function by inhibiting the growth of pathogenic microorganisms and regulating neurotransmitter activity, influencing the gut-brain axis. However, selecting appropriate probiotic strains and dosing regimens is crucial because of potential adverse effects, such as infections and allergic reactions.

Conclusions: Probiotics, specifically S boulardii, offer a promising avenue for IBS management by modulating gut microbiota. However, further research is necessary to delineate the precise mechanisms of action, optimal strains, dosing regimens for IBS treatment, and potential risks associated with long-term use. A comprehensive approach incorporating probiotics, a low-FODMAP diet, and cognitive-behavioral therapy may provide effective management of IBS symptoms.

Keywords: Blastocystis; Gut microbiota; Gut–brain axis; Irritable bowel syndrome; Probiotics; Saccharomyces boulardii.

PubMed Disclaimer

Conflict of interest statement

The authors have indicated that they have no conflicts of interest regarding the content of this article.

Figures

Figure 1
Figure 1
Types and alarming features of irritable bowel syndrome (IBS).
Figure 2
Figure 2
Irritable bowel syndrome triggered by different factors.
Figure 3
Figure 3
Method for determining irritable bowel syndrome (IBS). LTL = leukocyte telomere length; ML = machine learning; PCR = polymerase chain reaction.
Figure 4
Figure 4
Estimated effects of probiotics on irritable bowel syndrome (IBS).
See this image and copyright information in PMC

References

    1. Sisson G., Ayis S., Sherwood R.A., Bjarnason I. Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome - a 12-week double-blind study. Aliment. Pharmacol. Ther. Jul. 2014;40(1):51–62. doi: 10.1111/apt.12787. - DOI - PubMed
    1. Quigley E.M.M., et al. A Global Perspective on Irritable Bowel Syndrome: A Consensus Statement of the World Gastroenterology Organisation Summit Task Force on Irritable Bowel Syndrome. J. Clin. Gastroenterol. May 2012;46(5):356–366. doi: 10.1097/MCG.0b013e318247157c. - DOI - PubMed
    1. Zhu C., et al. Determine independent gut microbiota-diseases association by eliminating the effects of human lifestyle factors. BMC Microbiol. Jan. 2022;22(1):4. doi: 10.1186/s12866-021-02414-9. - DOI - PMC - PubMed
    1. Ceccherini C., Daniotti S., Bearzi C., Re I. Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review of Clinical Trials and Multi-Criteria Decision Analysis. Nutrients. Jun. 2022;14(13):2689. doi: 10.3390/nu14132689. - DOI - PMC - PubMed
    1. Yoon H., Park Y.S., Lee D.H., Seo J.-G., Shin C.M., Kim N. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J. Clin. Biochem. Nutr. 2015;57(2):129–134. doi: 10.3164/jcbn.15-14. - DOI - PMC - PubMed

LinkOut - more resources